Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE-ATTAIN-ADOLESCENTS
NCT06672939Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Orforglipron with Placebo (2 arms). Primary endpoint: Percent Change from Baseline in Body Mass Index at 72 weeks. Started Nov 2024; status: recruiting.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06672939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672939.